Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Christel Fontaine, Nele Claes, Marie-Pascale Graas, Khalil Kargar Samani, Peter Vuylsteke & Christof Vulsteke. (2021) Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg. Acta Clinica Belgica 76:1, pages 10-15.
Read now
Read now
Roberto Guariglia, Maria Carmen Martorelli, Rosa Lerose, Donatella Telesca, Maria Rita Milella & Pellegrino Musto. (2016) Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics: Targets and Therapy 10, pages 1-8.
Read now
Read now
Jonathan Hoggatt, Tiffany A Tate & Louis M Pelus. (2015) Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. International Journal of Nanomedicine 10, pages 2647-2652.
Read now
Read now
Matteo Lambertini, Arlindo R Ferreira, Lucia Del Mastro, Romano Danesi & Paolo Pronzato. (2015) Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert Opinion on Biological Therapy 15:12, pages 1799-1817.
Read now
Read now
Articles from other publishers (13)
Zekeriya Hannarici, Ali Yılmaz, Mehmet Emin Buyukbayram, Aykut Turhan, Salim Başol Tekin & Mehmet Bilici. (2022) Lipegfilgrastim may cause hyperleukocytosis. Journal of Oncology Pharmacy Practice 28:8, pages 1902-1905.
Crossref
Crossref
Hartmut Link, Stephen F. Thompson, Marc Tian, Jennifer S. Haas, Dominic Meise, Christopher Maas & Stamen Dimitrov. (2022) A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany. Supportive Care in Cancer 30:11, pages 9317-9327.
Crossref
Crossref
Hartmut Link. (2022) Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). Supportive Care in Cancer 30:9, pages 7067-7077.
Crossref
Crossref
Soyoung Lee, Kyung Taek Hong, Seol Ju Moon, Jung Yoon Choi, Che Ry Hong, Hee Young Shin, Joo‐Youn Cho, In‐Jin Jang, Kyung‐Sang Yu, Jaeseong Oh & Hyoung Jin Kang. (2021) Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G‐CSF, in Pediatric Patients with Solid Tumors. Clinical Pharmacology & Therapeutics 111:1, pages 293-301.
Crossref
Crossref
Mark Clemons, Dean Fergusson, Anil A. Joy, Kednapa Thavorn, Judith Meza-Junco, Julie Price Hiller, John Mackey, Terry Ng, Xiaofu Zhu, Mohammed F.K. Ibrahim, Marta Sienkiewicz, Deanna Saunders, Lisa Vandermeer, Gregory Pond, Bassam Basulaiman, Arif Awan, Lacey Pitre, Nancy A. Nixon, Brian Hutton & John F. Hilton. (2021) A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. The Breast 58, pages 42-49.
Crossref
Crossref
Axel S. Merseburger, Götz Geiges, Jörg Klier, Martin Wiesholzer & Petra Pichler. (2021) Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting. Frontiers in Oncology 11.
Crossref
Crossref
Hartmut Link, G. Illerhaus, U. M. Martens, A. Salar, R. Depenbusch, A. Köhler, M. Engelhardt, S. Mahlmann, M. Zaiss, A. Lammerich, P. Bias & A. Buchner. (2020) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Supportive Care in Cancer 29:5, pages 2519-2527.
Crossref
Crossref
A. Partanen, J. Valtola, A. Ropponen, H. Kuitunen, O. Kuittinen, K. Vasala, L. Ågren, K. Penttilä, L. Keskinen, M. Pyörälä, T. Nousiainen, T. Selander, P. Mäntymaa, J. Pelkonen, V. Varmavuo & E. Jantunen. (2018)
Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34
+
cells in non‐Hodgkin lymphoma patients
. Transfusion 59:1, pages 325-334.
Crossref
Crossref
Cornelius F. Waller, Renger G. Tiessen, Tracey E. Lawrence, Andrew Shaw, Mark Shiyao Liu, Rajiv Sharma, Mark Baczkowski, Mudgal A. Kothekar, Catherine E. Micales, Abhijit Barve, Gopinath M. Ranganna & Eduardo J. Pennella. (2018) A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. Journal of Cancer Research and Clinical Oncology 144:6, pages 1087-1095.
Crossref
Crossref
Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes & Steven Simoens. (2017) Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Frontiers in Pharmacology 8.
Crossref
Crossref
Jana Ďurková. (2017) Lipegfilgrastim, effective option how to avoid chemotherapy-induced neutropenia. Klinická farmakologie a farmacie 31:1, pages 3-10.
Crossref
Crossref
Afsaneh Abdolzade-Bavil, Aaron von Kerczek, Bridget A. Cooksey, Thomas Kaufman, Philip A. Krasney, Laurie Pukac, Matthias Görlach, Andreas Lammerich, Christian Scheckermann, Hermann Allgaier, Wenyan David Shen & Patrick M. Liu. (2016) Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile. The Journal of Clinical Pharmacology 56:2, pages 186-194.
Crossref
Crossref
Linglong Zou, Anton Buchner, Martin Roberge & Patrick M. Liu. (2016) Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy. Journal of Immunology Research 2016, pages 1-7.
Crossref
Crossref